Wound Care Global Market Report 2023: Sector to Reach $29.57 Billion by 2030 at a 4.15% CAGR – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Wound Care Market Size, Share & Trends Analysis Report By Product (Advanced, Surgical), By Application (Acute, Chronic), By End-use, By Mode of Purchase, By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030” report has been added to ResearchAndMarkets.com’s offering. The global wound care market size is anticipated to reach USD 29.57 … [Read more…]

Mara Files Counter Claim in UK Defending Patent Infringement Allegations Made by DSM for Its Algal Lipid Technologies

Initiates patent invalidation procedure for DSM patents at the European Patent Office HALIFAX, Nova Scotia–(BUSINESS WIRE)–Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today they have filed a counterclaim in the UK defending their algal lipid technologies in response to allegations levied by DSM for patent infringement. In addition, Mara has initiated … [Read more…]

Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway COPENHAGEN, Denmark–(BUSINESS WIRE)–Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop … [Read more…]

Akthelia Pharmaceuticals and the University of Iceland Secure a €6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR)

Collaborative IN-ARMOR project aims to advance novel innate immune system inducers for a healthier future REYKJAVIK, Iceland–(BUSINESS WIRE)–#AMR–Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, and the University of Iceland, are proud to announce the successful joint award of a €6 million EU Horizon Grant to fund the groundbreaking IN-ARMOR project. The project … [Read more…]

Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

Invir.IO® based oncolytic virus TG6050, is armed with IL-12 and an anti-CTLA4 antibody. A Phase I trial (Delivir) recently started enrolling patients with advanced non-small cell lung cancer (NSCLC) STRASBOURG, France–(BUSINESS WIRE)–#HBV–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, presented promising preclinical data … [Read more…]

ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens

A retrospective chart review interim analysis demonstrated that cefiderocol achieved clinical cure in 65% and 60% of patients with Pseudomonas aeruginosa and Acinetobacter baumannii respectively, the majority of whom were severely ill with comorbidities. OSAKA, Japan–(BUSINESS WIRE)–Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces key data … [Read more…]

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer’s Dementia

The Prescription Drug User Fee Act (PDUFA) target action date is May 10, 2023 PRINCETON, N.J. & DEERFIELD, Ill.–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc., (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food … [Read more…]

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

– Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 BOSTON & WILMINGTON, Del.–(BUSINESS WIRE)–MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today announced final five-year follow-up data from the … [Read more…]

Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023

NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today released preclinical data from the company’s portfolio of KIF18A inhibitors at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando. Volastra’s KIF18A portfolio consists of two clinical-stage highly differentiated, novel, first-in-class KIF18A inhibitors: recently in-licensed sovilnesib … [Read more…]

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant chemotherapy alone WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant chemotherapy before surgery and … [Read more…]